Yesterday, Thursday, February 26, the Spanish Association Against Cancer (AECC) held an event in Barcelona to present the research grants awarded for1
A study led by Clínic Barcelona Comprehensive Cancer Centre (4CB)- – driven by Clínic Barcelona, IDIBAPS and UB-, and sponsored by SOLTI, shows that1
The international DESTINY-Breast05 trial, published in The New England Journal of Medicine, demonstrates that the antibody-drug conjugate trastu1
The event addressed emotional, sexual, bureaucratic and research-related aspects, with a multidisciplinary and participatory approach.
Researchers from the Clínic Barcelona Comprehensive Cancer Center—driven by Hospital Clínic Barcelona, IDIBAPS, and the University of Barcelona—toget1
Researchers from Hospital Clínic-IDIBAPS have led a study that has found a correlation between anti-tumour immunological activity and longevity in br1
Over the next three years, the chosen project, led by Roger Gomis (IRB) in consortium with Aleix Prat (Clínic-IDIBAPS), will study the factors that c1
Researchers from the Clínic-IDIBAPS have coordinated a study that analyses the efficacy of anti-PD-1/PD-L1 immune checkpoint inhibitors (ICIs) combin1
One of the highlights of the Clínic-IDIBAPS participation in the European Society for Medical Oncology (ESMO) 2024 Congress was Dr. Josep M. Llovet’s1
A study promoted by SOLTI and published in Nature Communications describes the tumour biology associated with the activity of the drug patritumab der1
